HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Hermann Brustmann Selected Research

Carcinoma (Carcinomatosis)

7/2008Epidermal growth factor receptor expression in serous ovarian carcinoma: an immunohistochemical study with galectin-3 and cyclin D1 and outcome.
4/2007Poly(adenosine diphosphate-ribose) polymerase expression in serous ovarian carcinoma: correlation with p53, MIB-1, and outcome.
1/2007Poly(ADP-ribose) polymerase (PARP) and DNA-fragmentation factor (DFF45): expression and correlation in normal, hyperplastic and neoplastic endometrial tissues.
1/2006Galectin-3 and CD1a-positive dendritic cells are involved in the development of an invasive phenotype in vulvar squamous lesions.
1/2006DNA fragmentation factor (DFF45): expression and prognostic value in serous ovarian cancer.
9/2005Immunohistochemical detection of human telomerase reverse transcriptase (hTERT) and c-kit in serous ovarian carcinoma: a clinicopathologic study.
10/2004Vascular endothelial growth factor expression in serous ovarian carcinoma: relationship with topoisomerase II alpha and prognosis.
1/2004Expression of cellular apoptosis susceptibility protein in serous ovarian carcinoma: a clinicopathologic and immunohistochemical study.
1/2003Galectin-3 expression in normal, hyperplastic, and neoplastic endometrial tissues.
1/2002Apoptotic bodies as a morphological feature in serous ovarian carcinoma: correlation with nuclear grade, Ki-67 and mitotic indices.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Hermann Brustmann Research Topics

Disease

18Neoplasms (Cancer)
03/2015 - 01/2002
11Carcinoma (Carcinomatosis)
07/2008 - 01/2002
6Squamous Cell Carcinoma (Epidermoid Carcinoma)
11/2012 - 08/2002
5Serous Cystadenoma
07/2008 - 01/2002
3Lichen Sclerosus et Atrophicus (Lichen Sclerosus)
05/2013 - 11/2011
2Prostatic Hyperplasia (Benign Prostatic Hyperplasia)
12/2015 - 04/2015
2Prostatitis
12/2015 - 04/2015
2Endometrial Neoplasms (Endometrial Cancer)
01/2012 - 04/2005
2Endometrial Hyperplasia
01/2012 - 04/2005
2Hyperplasia
01/2007 - 04/2005
2Neoplasms, Cystic, Mucinous, and Serous
09/2005 - 01/2004
2Adenocarcinoma
04/2005 - 10/2004
1Inflammation (Inflammations)
12/2015
1Calculi (Calculus)
12/2015
1Neoplasm Metastasis (Metastasis)
04/2015
1Prostatic Neoplasms (Prostate Cancer)
04/2015
1Carcinogenesis
11/2011
1Glandular and Epithelial Neoplasms (Neoplasms, Glandular)
01/2011
1Uterine Cervical Dysplasia
10/2009
1Squamous Intraepithelial Lesions
10/2009
1Hemorrhage
11/2007
1Endometriosis
11/2007
1Dysmenorrhea (Menstrual Pain)
11/2007
1Ovarian Cysts (Ovarian Cyst)
11/2007
1Endometrioid Carcinoma
01/2007
1Cystadenoma
01/2002
1Cystadenocarcinoma
01/2002

Drug/Important Bio-Agent (IBA)

12ParaffinIBA
05/2013 - 01/2002
11Formaldehyde (Formol)FDA Link
05/2013 - 01/2002
5AntibodiesIBA
11/2011 - 01/2004
3Histones (Histone)IBA
03/2015 - 01/2011
3Proteins (Proteins, Gene)FDA Link
03/2015 - 01/2004
3Telomerase (Telomerase Reverse Transcriptase)IBA
11/2012 - 04/2005
3ErbB Receptors (EGF Receptor)IBA
01/2011 - 10/2007
3Galectin 3 (LGALS3)IBA
07/2008 - 01/2003
2Prostate-Specific Antigen (Semenogelase)IBA
12/2015 - 04/2015
2VimentinIBA
07/2013 - 01/2010
2SurvivinIBA
11/2012 - 11/2011
2EnzymesIBA
11/2012 - 04/2005
2Monoclonal AntibodiesIBA
10/2007 - 01/2006
2Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA
04/2007 - 01/2007
2Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
10/2004 - 01/2002
2trioctyl phosphine oxide (TOPO)IBA
01/2004 - 08/2002
2Hematoxylin (Haematoxylon)IBA
01/2002 - 01/2002
2Eosine Yellowish-(YS) (Eosin)IBA
01/2002 - 01/2002
1Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
12/2015
1Uric Acid (Urate)IBA
12/2015
1CholesterolIBA
12/2015
1C-Reactive ProteinIBA
12/2015
1Triglycerides (Triacylglycerol)IBA
12/2015
1Interleukin-2 Receptors (IL 2 Receptor)IBA
04/2015
1Interleukin-6 (Interleukin 6)IBA
04/2015
1Keratins (Keratin)IBA
07/2013
1Biological ProductsIBA
11/2011
1DNA (Deoxyribonucleic Acid)IBA
04/2011
1DesminIBA
01/2010
1ChromatinIBA
01/2010
1Nuclear Pore Complex Proteins (Nucleoporins)IBA
10/2009
1N 30IBA
10/2009
1Cyclin D1IBA
07/2008
1Levonorgestrel (Plan B)FDA LinkGeneric
11/2007
1Poly Adenosine Diphosphate RiboseIBA
04/2007
1caspase-activated DNase inhibitorIBA
01/2007
1Type II DNA Topoisomerases (Topoisomerase II)IBA
10/2004
1Cellular Apoptosis Susceptibility ProteinIBA
01/2004
1Proliferating Cell Nuclear Antigen (PCNA)IBA
08/2002
1Alkaline PhosphataseIBA
01/2002
1A-factor (Streptomyces)IBA
01/2002
1Indicators and Reagents (Reagents)IBA
01/2002

Therapy/Procedure

1Transurethral Resection of Prostate (TURP)
12/2015
1Intrauterine Devices (Intrauterine Device)
11/2007
1Contraception (Birth Control)
11/2007
1Laparotomy
11/2007